Veru INC DEF 14A proxy statements

Veru Inc. is calling its shareholders to an Annual Meeting on March 12, 2026, to vote on key proposals including the election of directors, auditor ratification, and a significant amendment to its equity incentive plan.

Veru Inc. has announced the engagement of Morrow Sodali LLC as a proxy solicitor for its upcoming Special Meeting of Shareholders on July 25, 2025, at a fee of $12,500 plus expenses.

VERU INC. has filed a definitive proxy statement (DEFA14A) with the SEC, providing information for its upcoming shareholder meeting.

Veru Inc. is seeking shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-20 to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement, aiming to avoid delisting and attract broader investor interest.

Veru Inc. has filed a definitive proxy statement with the SEC in accordance with Section 14(a) of the Securities Exchange Act of 1934.

Veru Inc. has scheduled its 2025 Annual Meeting of Shareholders for March 13, 2025, to vote on director elections, auditor ratification, and an equity incentive plan amendment.

Veru Inc. has adjourned its 2024 Annual Meeting due to a lack of quorum and hired Morrow Sodali LLC to solicit proxies.

Veru Inc. has adjourned its 2024 Annual Meeting of Shareholders to June 27, 2024, due to the absence of a quorum.

Veru Inc. has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

Veru Inc. has amended its proxy statement and postponed its annual meeting to June 18, 2024, due to errors identified in its historical financial statements, leading to a restatement in its Annual Report on Form 10-K/A.

Veru Inc. has set its 2024 Annual Meeting of Shareholders for June 18, 2024, following the filing of its 2023 Form 10-K/A and Q1 2024 Form 10-Q.

Veru Inc. has rescheduled its 2024 Annual Meeting of Shareholders to allow investors time to review restated financial statements, expected to be filed by April 15, 2024, due to overestimated research and development expenses.